Loading stock data…
PRAX
$346.84+3.64 (+1.06%)
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $346.84. Wall Street consensus targets $651.29 (17 analysts), implying a +87.8% move over the next 12 months. The stock is currently near its 52-week high of $358.76, remaining 62.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +87.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$346.84
Potential Downside
0%
Whystock Fair Value$346.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$651.29+87.8%
Range$166.00 – $1245
Fundamentals
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.58%
Volume
Today's trading volume
388,388
Recent News
Praxis (PRAX) Q1 2026 Earnings Call Transcript
Marcio Souza: Thank you, Dan, and good morning, everyone, and thanks for joining Praxis' First Quarter 2026 Conference Call. Building on a remarkable 2025, we have continued executing across our portfolio in our journey to become a commercial company with strong momentum building across 4 late-stage assets, representing more than $20 billion in peak sales potential.
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On May 8, TheFly reported that a Wedbush analyst bumped up Praxis Precision Medicines, Inc. (NASDAQ:PRAX)’s price target from $130 to $166. It maintained an “Underperform” rating and flagged concerns about the ulixacaltamide filing […]
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 results and pipeline updates on the company’s earnings call. President and Chief Executive Officer Ma
Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary
Moby summary of Praxis Precision Medicines, Inc.'s Q1 2026 earnings call
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge?
Praxis Precision Medicines, Inc. has already called its 2026 virtual annual meeting for June 10 to vote on director elections, auditor ratification, and an advisory Say-on-Pay proposal, following past-year progress such as positive Phase 3 ulixacaltamide data in essential tremor and an early new drug application filing. The company is pairing these clinical and regulatory advances with performance-based restricted stock units and has attracted a more than 5% passive stake from Vanguard...